Overview
- Genmab said it will discontinue further clinical development of acasunlimab following a portfolio review and competitive reassessment.
- Resources will shift to EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S), which are progressing in late-stage studies.
- Management stated the decision does not change full‑year 2025 financial guidance.
- U.S.-listed shares fell about 2% in premarket trading after the announcement.
- Acasunlimab, a 4‑1BB‑activating bispecific tested in late-stage solid tumor trials including NSCLC, became solely a Genmab program after BioNTech exited in 2024, and the petosemtamab asset entered the portfolio via the September Merus acquisition.